The signature based on seven genomic instability-related genes could predict the prognosis of acute myeloid leukemia patients

References

• Roloff GW, Griffiths EA. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. Hematology Am Soc Hematol Educ Program. 2018;2018(1):35–44.
   PubMedGoogle Scholar
• Medinger M, Lengerke C, Passweg J. Novel prognostic and therapeutic mutations in acute myeloid leukemia. Cancer Genomics Proteomics. 2016;13(5):317–329.
   PubMed Web of Science ®Google Scholar
• Lagunas-Rangel FA, Chavez-Valencia V, Gomez-Guijosa MA, et al. Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res. 2017;11(4):328–339.
   PubMedGoogle Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer. 2010;10(1):23–36.
   PubMed Web of Science ®Google Scholar
• Ambinder AJ, Levis M. Potential targeting of FLT3 acute myeloid leukemia. Haematologica. 2021;106(3):671–681.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463–471.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475–486.
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Duijf PHG, Nanayakkara D, Nones K, et al. Mechanisms of genomic instability in breast cancer. Trends Mol Med. 2019;25(7):595–611.
   PubMed Web of Science ®Google Scholar
• Andor N, Maley CC, Ji HP. Genomic instability in cancer: teetering on the limit of tolerance. Cancer Res. 2017;77(9):2179–2185.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability – an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220–228.
   PubMed Web of Science ®Google Scholar
• Panuzzo C, Signorino E, Calabrese C, et al. Landscape of tumor suppressor mutations in acute myeloid leukemia. J Clin Med. 2020;9(3).
   PubMed Web of Science ®Google Scholar
• Rebechi MT, Pratz KW. Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression. Leuk Lymphoma. 2017;58(9):1–11.
   PubMed Web of Science ®Google Scholar
• Teye EK, Sido A, Xin P, et al. PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. Oncotarget. 2017;8(18):29887–29905.
   PubMedGoogle Scholar
• Lee JK, Choi YL, Kwon M, et al. Mechanisms and consequences of cancer genome instability: lessons from genome sequencing studies. Annu Rev Pathol. 2016;11:283–312.
   PubMed Web of Science ®Google Scholar
• Anandakrishnan R, Varghese RT, Kinney NA, et al. Estimating the number of genetic mutations (hits) required for carcinogenesis based on the distribution of somatic mutations. PLoS Comput Biol. 2019;15(3):e1006881.
   PubMed Web of Science ®Google Scholar
• Fancello L, Gandini S, Pelicci PG, et al. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7(1):183.
   PubMed Web of Science ®Google Scholar
• Valero C, Lee M, Hoen D, et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat Genet. 2021;53(1):11–15.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. Clusterprofiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.
   PubMed Web of Science ®Google Scholar
• Mettu RK, Wan YW, Habermann JK, et al. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types. Int J Biol Markers. 2010;25(4):219–228.
   PubMed Web of Science ®Google Scholar
• Park DJ, Kwon A, Cho BS, et al. Characteristics of DNMT3A mutations in acute myeloid leukemia. Blood Res. 2020;55(1):17–26.
   PubMed Web of Science ®Google Scholar
• Burchert A. Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia. Haematologica. 2021;106(3):664–670.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–3485.
   PubMed Web of Science ®Google Scholar
• Tsirogianni M, Grigoriou E, Kapsimalli V, et al. Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine. Leuk Lymphoma. 2019;60(10):2457–2463.
   PubMed Web of Science ®Google Scholar
• Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123.
   PubMed Web of Science ®Google Scholar
• Zeng H, Wu H, Yan M, et al. Characterization of a 4 lncRNAs-based prognostic risk scoring system in adults with acute myeloid leukemia. Leuk Res. 2020;88:106261.
   PubMed Web of Science ®Google Scholar
• Wang X, Mak PY, Mu H, et al. Combinatorial inhibition of focal adhesion kinase and BCL-2 enhances antileukemia activity of venetoclax in acute myeloid leukemia. Mol Cancer Ther. 2020;19(8):1636–1648.
   PubMed Web of Science ®Google Scholar
• Ney GM, McKay L, Koschmann C, et al. The emerging role of Ras pathway signaling in pediatric cancer. Cancer Res. 2020;80(23):5155–5163.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Bewersdorf JP, Boddu PC, et al. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert Rev Anticancer Ther. 2019;19(8):717–729.
   PubMed Web of Science ®Google Scholar
• Erbani J, Tay J, Barbier V, et al. Acute myeloid leukemia chemo-resistance is mediated by E-selectin receptor CD162 in bone marrow niches. Front Cell Dev Biol. 2020;8:668.
   PubMed Web of Science ®Google Scholar
• Barbier V, Erbani J, Fiveash C, et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nat Commun. 2020;11(1):2042.
   PubMed Web of Science ®Google Scholar
• Ruvolo PP, Ma H, Ruvolo VR, et al. LGALS1 acts as a pro-survival molecule in AML. Biochim Biophys Acta Mol Cell Res. 2020;1867(10):118785.
   PubMed Web of Science ®Google Scholar
• Alanazi B, Munje CR, Rastogi N, et al. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia. 2020;34(2):427–440.
   PubMed Web of Science ®Google Scholar
• Ma BB, Zhang TJ, Wang CZ, et al. Methylation-independent CRIP1 expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia. Am J Transl Res. 2020;12(9):4840–4852.
   PubMed Web of Science ®Google Scholar
• Ye C, Ma S, Xia B, et al. Weighted gene coexpression network analysis identifies cysteine-rich intestinal protein 1 (CRIP1) as a prognostic gene associated with relapse in patients with acute myeloid leukemia. Med Sci Monit. 2019;25:7396–7406.
   PubMed Web of Science ®Google Scholar